Copied
 
 
2023, DKK
19.06.2024
Bruttoresultat

92.376'

Primær drift

23.472'

Årets resultat

17.180'

Aktiver

183''

Kortfristede aktiver

99.822'

Egenkapital

76.188'

Afkastningsgrad

13 %

Soliditetsgrad

42 %

Likviditetsgrad

161 %

Resultat
19.06.2024
Årsrapport
2023
19.06.2024
2022
30.06.2023
2021
30.05.2022
2020
30.06.2021
2019
02.09.2020
2018
22.06.2019
2017
25.06.2018
2016
20.06.2017
2015
16.06.2016
Nettoomsætning
Bruttoresultat92.375.70772.802.06950.461.69728.061.085
Resultat af primær drift23.471.99722.677.09020.742.45212.984.545
Indtægter af kapitalandele (tilknyttede og associerede) 0000
Finansielle indtægter46.9248.62086.20963.250
Finansieringsomkostninger-2.149.171-1.736.186-470.102-289.521
Andre finansielle omkostninger0000
Resultat før skat22.355.52920.949.52420.351.07912.757.182
Resultat17.179.52916.212.18015.721.16710.262.982
Forslag til udbytte-2.200.0000-1.000.0000
Aktiver
19.06.2024
Årsrapport
2023
19.06.2024
2022
30.06.2023
2021
30.05.2022
2020
30.06.2021
2019
02.09.2020
2018
22.06.2019
2017
25.06.2018
2016
20.06.2017
2015
16.06.2016
Kortfristede varebeholdninger0000
Kortfristede tilgodehavender fra salg og tjenesteydelser 98.542.27294.538.02738.591.97815.661.363
Likvider1.279.5182.942.9991.896.17719.644.229
Kortfristede aktiver99.821.79097.481.02640.488.15535.305.592
Immaterielle aktiver og goodwill0000
Finansielle anlægsaktiver26.056.71719.598.99318.606.0078.124.611
Materielle aktiver57.084.42953.887.90321.623.4976.551.112
Langfristede aktiver83.141.14673.486.89640.229.50414.675.723
Aktiver182.962.936170.967.92280.717.65949.981.315
Aktiver
19.06.2024
Passiver
19.06.2024
Årsrapport
2023
19.06.2024
2022
30.06.2023
2021
30.05.2022
2020
30.06.2021
2019
02.09.2020
2018
22.06.2019
2017
25.06.2018
2016
20.06.2017
2015
16.06.2016
Forslag til udbytte2.200.00001.000.0000
Egenkapital76.188.39053.918.66638.989.77123.268.604
Hensatte forpligtelser5.616.000440.000992.67478.810
Langfristet gæld til banker840.3561.113.07100
Anden langfristet gæld000
Leverandører af varer og tjenesteydelser6.837.41213.371.37310.204.8445.745.912
Kortfristede forpligtelser62.039.58877.394.86640.735.21426.633.901
Gældsforpligtelser101.158.546116.609.25640.735.21426.633.901
Forpligtelser101.158.546116.609.25640.735.21426.633.901
Passiver182.962.936170.967.92280.717.65949.981.315
Passiver
19.06.2024
Nøgletal
19.06.2024
Årsrapport
2023
19.06.2024
2022
30.06.2023
2021
30.05.2022
2020
30.06.2021
2019
02.09.2020
2018
22.06.2019
2017
25.06.2018
2016
20.06.2017
2015
16.06.2016
Afkastningsgrad 12,8 %13,3 %25,7 %26,0 %
Dækningsgrad Na.Na.Na.Na.
Resultatgrad Na.Na.Na.Na.
Varelagerets omsætningshastighed Na.Na.Na.Na.
Egenkapitals-forretning 22,5 %30,1 %40,3 %44,1 %
Payout-ratio 12,8 %Na.6,4 %Na.
Gældsdæknings-nøgletal 1.092,1 %1.306,1 %4.412,3 %4.484,8 %
Soliditestgrad 41,6 %31,5 %48,3 %46,6 %
Likviditetsgrad 160,9 %126,0 %99,4 %132,6 %
Resultat
19.06.2024
Gæld
19.06.2024
Årsrapport
19.06.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 19.06.2024)
Information om virksomhedens regnskabsklasse:The annual report for Minerva Imaging ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class C enterprises (medium sized enterprises).
Oplysning om pantsætninger og sikkerhedsstillelser:14. Charges and security For security for the company's and the group's bank commitments, the company has provided security in company assets representing a nominal value of 20.000 t.kr. This security comprises the assets below, stating the carrying amounts: DKK in thousands Trade receivables 32.227 Other fixtures, fittings, tools and equipment 16.591 Furthermore, the company has provided security in investments in group enterprises with a carrying amount of 22.726 t.kr., cf. note 6, for security for the group's bank commitment. The company has guaranteed the subsidiary, Bioadvice A/S, bank commitment. Fixtures, fittings, tools, and equipment representing a carrying amount of 40.493 t.kr.at 31 December 2023, cf. note 5, have been financed by means of finance leases. At 31 December 2023, this lease liability totals 44.362 t.kr. The company's total security for group enterprises amounts to a maximum of 123.362 t.kr.
Beretning
19.06.2024
Dato for ledelsens godkendelse af årsrapporten:2024-06-14
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Managing Director have approved the annual report of Minerva Imaging ApS for the financial year 1 January - 31 December 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Description of key activities of the company Minerva Imaging’s vision is to become the leading contract research and contract development organization for targeted radionuclide therapy, enabling improved treatment regimens for cancer patients with a focus on the use of advanced animal models within oncology and cardiovascular diseases and in vivo molecular imaging for translational research and drug development. We aim to excel in delivering customized cancer radiopharmaceutical research and serve as an extended research team to our collaborators. We have built a global leading R&D platform for targeted radionuclide therapy and Contract Development and Manufacturing (CDMO) to enable integrated planning and faster execution of promising new radionuclide theragnostic projects in close collaboration with leading researchers, biotech, and pharmaceutical companies. Minerva is at the forefront of R&D in the theragnostic area. We are in a very fast-paced environment, where our researchers directly impact the advancement of new improved, and lifesaving drugs for seriously ill cancer patients. We have the ambition to make a difference for our clients, collaborating on advancing new treatment modalities for patients.